The company's legacy business model, reliant on physical stores, faces an existential threat from disruption by online, tech-enabled healthcare platforms and is considered a poor investment.

Business model is considered at risk of becoming obsolete due to disruption from telehealth companies like HIMS and e-commerce.

Explicitly called 'dead' alongside Rite Aid due to the disruption from Amazon's expansion into pharmacy services.

Mentioned as a traditional pharmacy that is struggling as consumers increasingly move to buy medications online.

Will be deleted from the S&P 500 index.

While not directly targeted by insulin price caps, the company could experience indirect, downstream effects. Changes in the pricing of high-volume drugs can potentially affect overall pharmacy revenue and margin dynamics, which is a secondary consideration for investors.